{"id":"ribavirin-sch-018908","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":null,"effect":"Teratogenicity / reproductive toxicity"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dyspnea"},{"rate":"10-15","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL513136","moleculeType":"Small molecule","molecularWeight":"397.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is converted intracellularly to its active triphosphate form, which depletes cellular GTP pools and directly inhibits viral RNA-dependent RNA polymerase. This dual mechanism reduces viral replication across multiple RNA viruses. It has broad-spectrum antiviral activity and is commonly used in combination with other antivirals for enhanced efficacy.","oneSentence":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:01.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals)"},{"name":"Severe respiratory syncytial virus (RSV) infection"},{"name":"Hemorrhagic fever with renal syndrome"},{"name":"Lassa fever"}]},"trialDetails":[{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT01544920","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-30","conditions":"Hepatitis C, Chronic","enrollment":737},{"nctId":"NCT00687219","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":102},{"nctId":"NCT00687544","phase":"PHASE4","title":"Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Hepatitis C, Chronic, Hepacivirus, HIV Infections","enrollment":11},{"nctId":"NCT00723632","phase":"","title":"Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":901},{"nctId":"NCT00724451","phase":"","title":"Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":1128},{"nctId":"NCT00725842","phase":"","title":"Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":97},{"nctId":"NCT00724893","phase":"","title":"Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2430},{"nctId":"NCT00736242","phase":"","title":"Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Chronic Hepatitis C, Hepatitis C, HIV Infections","enrollment":232},{"nctId":"NCT01054742","phase":"","title":"Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Hepatitis C","enrollment":2},{"nctId":"NCT01098097","phase":"","title":"Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06","conditions":"Hepatitis C, Chronic","enrollment":963},{"nctId":"NCT00724620","phase":"PHASE4","title":"PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)","status":"COMPLETED","sponsor":"Schering-Plough","startDate":"2005-06","conditions":"Hepatitis C, Chronic","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rebetol"],"phase":"marketed","status":"active","brandName":"Ribavirin (SCH 018908)","genericName":"Ribavirin (SCH 018908)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity. Used for Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}